There has been limited research on the prognosis differences in patients with gastric stromal tumor invasion of the plasma membrane surface. This study intended to investigate whether there is a difference in prognosis in patients with endogenous or exogenous 2–5 cm diameter GISTs.
Methods
We retrospectively analyzed the clinicopathological and follow-up data of gastric stromal tumor patients, all of whom underwent surgical resection for primary GIST at Nanjing Drum Tower Hospital from December 2010 to February 2022. We classified patients based on tumor growth patterns and then investigated the association between tumor growth patterns and clinical outcomes. Progression-free survival (PFS) and overall survival (OS) were calculated by the Kaplan‒Meier method.
Results
A total of 496 gastric stromal tumor patients were enrolled in this study, among which 276 patients had tumors of 2–5 cm in diameter. Of these 276 patients, 193 had exogenous tumors, and 83 had endogenous tumors. Tumor growth patterns were significantly related to age, rupture status, resection style, tumor site, tumor size, and intraoperative bleeding. According to Kaplan‒Meier curve analysis, the tumor growth pattern among patients with 2–5 cm diameter tumors was significantly correlated with worse progression-free survival (PFS). Ultimately, multivariate analyses identified the Ki-67 index (P = 0.008), surgical history (P = 0.031), and resection style (P = 0.045) as independent prognostic markers for PFS.
Conclusions
Although gastric stromal tumors with a diameter of 2–5 cm are classified as low risk, the prognosis is lower for exogenous tumors than for endogenous tumors, and exogenous gastric stromal tumors have a risk of recurrence. Consequently, clinicians should be vigilant regarding the prognosis of patients with this type of tumor.
Hinweise
Chen Lin, Chao Sui, and Tingting Tao share first authorship.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most prevalent mesenchymal tumors in the gastrointestinal tract, with a primary occurrence in the stomach and secondary occurrence in the small intestine [1]. The annual incidence of GISTs is approximately 10–20 per million [2], and the median patient age associated with this incidence is approximately 60 years, with an equal distribution between sexes [3]. Pathogenetically, most gastrointestinal stromal tumors result from mutations in the KIT gene or platelet-derived growth factor receptor-α gene [4]. Patients with GISTs are increasingly being identified and treated in clinical practice, and surgical resection is the primary treatment, as GISTs are not responsive to radiotherapy or chemotherapy [5]. Tumor recurrence or progression in patients undergoing surgical resection is a significant challenge, with studies showing recurrence rates in approximately 50% of patients [6]. According to several analyses, tumor location, tumor size, and mitotic rate are important factors in assessing the prognostic outcome [7].
Gastric stromal tumors originate from the muscular layer of the gastric wall. According to their growth pattern, they are classified into exogenous or endogenous types. According to recent studies, the survival rate of patients with gastric stromal tumors is influenced by the location and size of the primary tumor [8]. According to the 2008 modified NIH risk classification, tumors are classified as knockdown risk, low risk, intermediate risk, and high risk [6]. Gastric stromal tumors with a diameter of 2–5 cm are classified as low risk. The current retrospective study found fewer cases of the endogenous type, which may be attributed to the safety of endoscopic resection for gastric stromal tumors smaller than 5 cm [9]. Most tumors less than 5 cm in diameter are of the endogenous type and are resected endoscopically. Numerous studies have investigated the correlations between biological behaviors and prognoses of gastric stromal tumors, including factors such as p53 [10], major cell types [11], tumor size [12], KIT mutation [13], cell density [14], and mitotic count [15]. Different tumor growth patterns have been studied in gastric stromal tumors and have been found to impact prognosis [16]. Our preliminary clinical study revealed that the level of serum CA125 can be used as an independent prognostic factor for gastrointestinal stromal tumors, providing new insights for clinical research [17]. This article discusses gastrointestinal stromal tumors (GISTs) with a diameter less than 5 cm, which predominantly exhibit an intraluminal growth pattern. In contrast, GISTs with a diameter between 5 and 10 cm exhibit both intraluminal and extraluminal growth patterns and can invade other organs. Up to 79% of GISTs demonstrate exogenous growth, while endogenous or mixed growth patterns are less common [18]. Our retrospective study analyzed patients with gastric stromal tumors with a diameter of 2–5 cm who were treated at Nanjing Drum Tower Hospital over a period of 12 years. We compared the clinicopathological characteristics and prognosis of endogenous and exogenous types of gastric stromal tumors to provide more guidance for clinicians in their treatment decisions.
Anzeige
Methods and materials
Patient section
This study retrospectively analyzed the clinicopathological and follow-up data of GIST patients who underwent surgical resection at the Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital, from December 2010 to February 2022. The diagnosis of GIST relied on the Chinese and NCCN guidelines. The inclusion criteria were as follows: (1) 18–80 years old, (2) surgical resection, (3) GIST pathological diagnosis, (4) detailed and complete medical data, (5) no preoperative chemotherapy, and (6) no preoperative recurrence of metastases. The exclusion criteria were as follows: (1) patients with other concomitant carcinomas, (2) no surgical resection, (3) missing follow-up data, (4) patients who underwent emergency surgery, and (5) joint organ removal. Finally, a total of 493 patients were enrolled. The screening process is shown in Fig. 1.
Fig. 1
Flow chart of final patient admission
×
Study design
This was a single-center retrospective study. The primary outcome was PFS, which was defined as the time from the date of first surgery to the date of gastric stromal tumor progression or death. Overall survival (OS) was defined as the time from the first surgery date to the date of death. In addition, the date of the last follow-up visit was the study endpoint for PFS in the absence of progression or death. An endogenous growth pattern was defined as an intact intraoperative gastric plasma surface without abnormalities, while an exogenous growth pattern was defined as the observation of new growth during an intraoperative exploration of the gastric plasma membrane surface. Presurgical clinical data for patients at our hospital were collected by clinical physicians. Follow-up after surgery was conducted by specialized researchers using outpatient records and telephone interviews. Our follow-up visits included patients’ adjuvant treatment, recurrent metastases, and survival and postoperative reviews. In this study, we first grouped patients according to their tumor growth pattern and explored the relationship of this pattern with clinical prognosis. A total of 276 patients with gastric stromal tumors ranging in diameter from 2 to 5 cm were included, 193 of these patients had exogenous tumors, and 83 patients had endogenous tumors. We focused on whether the differences between endogenous and exogenous tumors were associated with gastric stromal tumor prognosis. Additionally, we examined laboratory tests, pathological data, and other factors to identify their impact on the prognosis of patients with gastric stromal tumors.
Statistical analysis
SPSS 25.0 software (IBM Corporation, Armonk, NY, USA). The measurements were compared by independent samples t-test, while categorical variables were compared using the χ2 test or Fisher’s exact test. Examples (%) were used to express statistical information. Kaplan‒Meier analysis was used to plot the survival curves of the two groups, and the log-rank method was used to analyze the difference in survival rates between the two groups. Univariate and multivariate Cox proportional-hazard regression model analyses were used to identify independent factors for the recurrence of gastric stromal tumors. A P-value of less than 0.05 was considered to indicate statistical significance.
Results
Patient characteristics
Among the 496 patients initially included in this study, 375 had exogenous tumors, and 121 had endogenous tumors. The clinicopathological parameters between the two groups are compared in Table 1, which shows a significant difference in rupture status (P = 0.001), age (P = 0.023), resection style (P = 0.026), tumor site (P = 0.013), tumor size (P = 0.002), and intraoperative bleeding (P = 0.030). These findings indicate that the tumor growth pattern is associated with the tumor size. Gastric stromal tumors are categorized by size into three groups: < 2 cm, 2–5 cm, and > 5 cm. Tumors with a diameter of < 2 cm are considered to have a very low risk of recurrence and patient death, while those with a diameter of > 5 cm are considered to have a moderate to high risk and receive more attention from clinicians. Tumors with a diameter of 2–5 cm are traditionally classified as low risk, but they still pose a risk of recurrence, and clinicians may not pay enough attention to them [18]. Therefore, we selected gastric stromal tumors of 2–5 cm diameter for this retrospective study. Among the 276 patients with tumors of this size, 193 had exogenous tumors, and 83 had endogenous tumors. The clinicopathological parameters between the two groups are compared in Table 2, which shows a significant age difference (P = 0.002) and HB (P = 0.005). However, the growth pattern of tumors 2–5 cm in diameter was not associated with clinical characteristics, including mitotic index, imatinib treatment, patient sex, tumor site, and NIH risk grade.
Table 1
Association between tumor growth patterns and clinicopathological features
Characteristics
Exogenous (n = 375)
Endogenous (n = 121)
p-value
Age (%)
0.023
≤ 65
270 (76.1)
75 (61.9)
> 65
105 (23.9)
46 (38.1)
Gender (%)
0.987
Female
210 (43.5)
67 (55.4)
Male
165 (56.5)
54 (44.6)
Rupture (%)
0.001
No
370 (94.1)
120 (99.2)
Yes
5 (5.9)
1 (0.8)
Tumor site (%)
0.013
Small bend
130 (34.7)
38 (31.4)
Large bend
156 (41.6)
60 (49.6)
Fundus
89 (23.7)
23 (19.0)
Tumor size (%)
0.002
< 5 cm
37 (9.8)
11 (9.1)
2–5 cm
192 (51.2)
83 (68.6)
> 5 cm
146 (39.0)
27 (22.3)
Mitotic index (%)
0.403
≤ 5/HPF
268 (71.5)
92 (76.0)
> 5/HPF
107 (28.5)
29 (24.0)
NIH risk grade (%)
0.057
Extremely low or low
189 (50.4)
76 (62.8)
Moderate or high
186 (49.6)
45 (37.2)
CD117 (%)
0.775
( −) or ( +)
103 (27.5)
29 (24.0)
(+ +) or (+ + +)
272 (72.5)
95 (76.0)
CD34 (%)
0.696
( −) or ( +)
69 (18.4)
12 (10.0)
(+ +) or (+ + +)
306 (81.6)
109 (90.0)
Surgical history (%)
308 (82.1)
95 (78.5)
0.451
HB (X̄)
127
124
0.124
ALB (X̄)
40.4
39.95
0.172
Adjuvant imatinib (%)
279 (74.4)
87 (72.0)
0.671
Basic disease (%)
215 (57.3)
68 (56.2)
0.909
Resection style (%)
0.026
Mesenchymal resection
331 (88.3)
96 (79.3)
Distal gastrectomy
14 (3.7)
12 (10.0)
Proximal gastrectomy
18 (4.8)
10 (8.3)
Total gastrectomy
12 (3.2)
3 (2.4)
Surgery time (min)
120
115
0.884
Intraoperative bleeding(ml)
50
50
0.030
Table 2
Association between 2 and 5 cm tumor growth patterns and clinicopathological features
Characteristics
Exogenous (n = 193)
Endogenous (n = 83)
p-value
Age (%)
0.002
≤ 65
147 (76.1)
49 (75.9)
> 65
46 (23.9)
34 (24.1)
Gender (%)
0.412
Female
84 (43.5)
52 (62.6)
Male
109(56.5)
31 (37.4)
GI bleeding (%)
0.082
No
143 (78.8)
61 (73.5)
Yes
50 (21.2)
18 (26.5)
Tumor site (%)
0.052
Small bend
72 (37.3)
44 (53.0)
Large bend
73 (37.8)
23 (27.8)
Fundus
48 (24.9)
16 (19.2)
Adjuvant imatinib (%)
121 (46.2)
62 (23.7)
0.307
Mitotic index (%)
0.660
≤ 5/HPF
192 (70.1)
51 (63.0)
> 5/HPF
82 (29.9)
30 (37.0)
NIH risk grade (%)
0.248
Extremely low or low
157 (81.3)
64 (77.1)
Moderate or high
36 (18.7)
19 (22.9)
CD117 (%)
0.071
( −) or ( +)
55 (28.5)
18 (21.7)
(+ +) or (+ + +)
138 (71.7)
65 (78.3)
CD34 (%)
0.286
( −) or ( +)
48 (24.9)
10 (12.1)
(+ +) or (+ + +)
138 (71.5)
73(87.9)
Ki-67 index (%)
0.372
< 5%
155 (80.3)
64 (77.1)
≥ 5%
38 (19.7)
19 (22.9)
HB (X̄)
130
121
0.005
ALB (X̄)
40.3
39.7
0.078
Resection style (%)
0.200
Mesenchymal resection
179 (64.9%)
70 (25.4%)
Distal gastrectomy
6 (2.2%)
7 (2.5%)
Proximal gastrectomy
6 (2.2%)
5 (1.8%)
Total gastrectomy
1 (0.4%)
1 (0.4%)
Basic disease (%)
87 (31.5%)
43 (15.6%)
0.370
Surgical history (%)
37 (13.4%)
19 (6.9%)
0.588
Anzeige
Impact of exogenous and endogenous factors on prognosis
We regarded the tumor growth pattern as a variable in the Cox proportional-hazard regression model. Univariate analysis showed that resection style (P = 0.041, HR = 0.121, 95% CI: (0.016 ~ 0.914); tumor growth pattern (P = 0.048, HR = 0.130, 95% CI: 0.017 ~ 0.986); Ki-67 index (P = 0.005, HR = 1.206, 95% CI: 1.057 ~ 1.376); and surgical history (P = 0.049, HR = 2.914, 95% CI: 1.004 ~ 8.461) were significantly associated with PFS (Table 3). Subsequently, multivariate analysis demonstrated that resection style (P = 0.045, HR = 2.015, 95% CI: 0.190 ~ 14.438), Ki-67 index (P = 0.008, HR = 1.070, 95% CI: 1.018 ~ 1.125), and surgical history (P = 0.031, HR = 3.066, 95% CI: 1.110 ~ 8.474) were independent predictive factors for PFS (Table 3).
Table 3
Cox proportional-hazard regression model analysis for PFS
Factors
Univariate analysis
PFS
Multivariate analysis
PFS
HR (95% CI)
p-value
HR (95% CI)
p-value
Age
0.070
≤ 65
Reference
> 65
1.041 (0.997 ~ 1.086)
Gender
0.659
Male
Reference
Female
1.234 (0.385 ~ 4.412)
GI bleeding
No
Reference
0.520
Yes
1.374 (0.521 ~ 3.625)
Growth pattern
0.048
0.058
Exogenous
Reference
Reference
Endogenous
0.130 (0.017 ~ 0.986)
7.070 (0.933 ~ 53.595)
Tumor site
0.887
Small bend
Large bend
Reference
Fundus
1.046 (0.562 ~ 1.945)
Resection style
0.041
0.045
Mesenchymal resection
Reference
Reference
Distal gastrectomy
0.121 (0.016 ~ 0.914)
2.015 (0.190 ~ 14.438)
Proximal gastrectomy
Total gastrectomy
Mitotic index
0.802
≤ 5/HPF
Reference
> 5/HPF
1.261 (0.206 ~ 7.699)
NIH risk grade
0.798
Extremely low or low
Reference
Moderate or high
0.841 (0.224 ~ 3.162)
CD117
0.747
( −) or ( +)
Reference
(+ +) or (+ + +)
0.590 (0.024 ~ 14.513)
CD34
0.813
( −) or ( +)
Reference
(+ +) or (+ + +)
1.471 (0.060 ~ 36.235)
Ki-67 index
0.005
0.008
≤ 5%
Reference
Reference
> 5%
1.206 (1.057 ~ 1.376)
1.070 (1.018 ~ 1.125)
Basic disease
Reference
0.788
1.144 (0.429 ~ 3.049)
Surgical history
Reference
0.049
Reference
0.031
2.914 (1.004 ~ 8.461)
3.066 (1.110 ~ 8.474)
Adjuvant imatinib
Reference
0.278
2.035 (0.564 ~ 7.342)
Table 4 shows that GI bleeding (P = 0.044, HR = 0.293, 95% CI: 0.088 ~ 0.968) and basic disease (P = 0.036, HR = 0.276, 95% CI: 0.083 ~ 0.921) were significantly correlated with OS by univariate analysis. The multivariate analysis showed no independent risk factors for OS (Table 4).
Table 4
Cox proportional-hazard regression model analysis for OS
Factors
Univariate analysis
RFS
Multivariate analysis
RFS
HR (95% CI)
p-value
HR (95% CI)
p-value
Age
0.162
≤ 65
Reference
> 65
0.951 (0.886 ~ 1.020)
Gender
0.614
Male
Reference
Female
0.672 (0.144 ~ 3.144)
GI bleeding
No
Reference
0.044
Reference
0.179
Yes
0.293 (0.088 ~ 0.968)
− 1.348 (− 14.456 ~ 2.707)
Growth pattern
0.938
Exogenous
Reference
Endogenous
0.000 (0.000 ~ 7.291E)
Tumor site
0.839
Small bend
Large bend
Reference
Fundus
1.099 (0.442 ~ 2.734)
Resection style
0.695
Mesenchymal resection
Reference
Distal gastrectomy
0.728 (0.149 ~ 3.757)
Proximal gastrectomy
Total gastrectomy
Mitotic index
0.128
≤ 5/HPF
Reference
> 5/HPF
0.001 (0.000 ~ 8.248)
NIH risk grade
0.117
Extremely low or low
Reference
Moderate or high
50.034 (0.224 ~ 3.162)
CD117
0.925
( −) or ( +)
Reference
(+ +) or (+ + +)
0.849 (0.027 ~ 26.498)
CD34
0.249
( −) or ( +)
Reference
(+ +) or (+ + +)
7.801 (0.237 ~ 257.082)
Ki-67 index
0.806
≤ 5%
Reference
> 5%
0.970 (0.760 ~ 1.237)
Basic disease
Reference
0.036
Reference
0.588
0.276 (0.083 ~ 0.921)
0.558 (− 7.005 ~ 12.538)
Surgical history
Reference
0.693
1.363 (0.293 ~ 6.348)
Adjuvant imatinib
Reference
0.686
1.289 (0.378 ~ 4.397)
Overall, the tumor growth pattern was found to be an independent risk factor for PFS (Table 3) but not for OS (Table 4).
Prognosis comparison between the two groups
Follow-up of these 276 patients ranged from 12 to 148 months. At the time of the last follow-up (Feb 2022), 21 patients were found to have gastric stromal tumors, and 14 patients were dead. The median follow-up time for this study was 33 months, with a median follow-up time of 80 months. According to Kaplan‒Meier curve analysis, tumor growth patterns (P = 0.021) were associated with PFS in patients with gastric stromal tumors (Fig. 2B). The PFS for patients with exogenous 2–5 cm gastric stromal tumors was 89.6%. The PFS for patients with endogenous 2–5 cm gastric stromal tumors was 98.7%. A P-value of less than 0.05 was considered to indicate statistical significance.
Fig. 2
Kaplan–Meier curves of PFS and OS with the exogenous and endogenous gastric stromal tumors 2–5 cm in diameter. A OS. B PFS
×
In a subsequent study of the effect of tumor growth patterns on OS (P = 0.722), we found no association between the two in the 276 patients with gastric stromal tumors we studied (Fig. 2A). Fewer patients with 2–5 cm diameter gastric stromal tumors died. The OS of patients with exogenous 2–5 cm gastric stromal tumors was 99%. The OS of patients with endogenous 2–5 cm gastric stromal tumors was 99%. A P-value above 0.05 was considered to indicate no statistical significance.
Discussion
This study was a single-center retrospective analysis. We retrospectively analyzed the clinicopathological data of 276 patients with 2–5 cm diameter gastric stromal tumors treated at Nanjing Drum Tower Hospital. Gastrointestinal stromal tumors are common mesenchymal tumors of the gastrointestinal tract. In recent years, with the development of diagnostic techniques, the diagnosis rate of gastric stromal tumors has gradually increased [19].
This study intended to explore the influencing factors of the clinical outcomes in Chinese patients with 2–5 cm diameter gastric stromal tumors with different tumor growth patterns through the integration and analysis of clinical pathological data. We focused on 2–5 cm diameter gastric stromal tumors to elucidate the exact relationship between tumor growth patterns and patient prognosis by combining preoperative laboratory tests and postoperative reexamination data. To the best of our knowledge, this research established a connection between tumor growth patterns and 2–5 cm diameter gastric stromal tumors for the first time.
In this study, we used PFS and OS as outcome measures and found that tumor growth patterns had a close relationship with worse PFS through Kaplan‒Meier curve analysis. Subsequently, we demonstrated that tumor growth patterns were independent risk factors for PFS, but similar results were not observed in the multivariate analysis of OS. In univariate analysis, bleeding and underlying diseases were considered prognostic factors for overall survival. However, in a more precise multivariate analysis, no independent prognostic factors related to overall survival were found. Additionally, there was no correlation between overall survival and the growth pattern (P = 0.722) of gastric stromal tumors (Table 4). A recent study examined the association between surface ulceration in gastrointestinal stromal tumors and their growth patterns, revealing a strong correlation between the two [20]. Our study showed the significance of resection style, Ki-67 index, and surgical history on PFS in patients with endogenous and exogenous tumors. Gastric stromal tumors tend to grow swollen in the submucosa and rarely involve lymph nodes [21]. Most gastric stromal tumors are endogenous, so most gastric mesenchymal tumors are resected surgically using endoscopy for relatively large-diameter tumors. Research also shows that full laparotomy is used when the endogenous type of tumor is in the lesser curvature in the stomach. The location of the endophytic tumor is unclear using plasmacytoma [22]. According to the 2019 NCCN guidelines, experienced surgeons are advised to opt for laparoscopic surgery in favorable sites such as the greater curvature of the stomach [23]. In this study, there were 96 cases of tumors in the large bend, 116 in the small bend, and 64 in the fundus (Table 2). In this retrospective study, we found that differences in surgical approach were factors affecting PFS in patients with direct 2–5 cm gastric stromal tumors. Ki67, also known as MKI67, is a proliferation-associated nuclear marker of tumor cells [24]. Gumurdulu et al. found that Ki67 was useful as a prognostic factor along with tumor size, mitotic index, and tumor grade [25]. In a previous study, Ki-67 was shown to be significantly associated with prognosis and tumor recurrence in GISTs [26]. Surgical resection is the primary treatment for localized disease and is the preferred approach for GISTs [27]. Ki67 in this study was likewise an independent factor that influenced PFS in patients with direct 2–5 cm gastric stromal tumors. Our study found that surgical history was also an important influencing factor for PFS, and patients with a history of surgery had a worse prognosis than those without a history of surgery. This study included 56 patients with surgical histories (Table 2).
Anzeige
The study had several limitations. First, this research was a retrospective examination, which means that selection bias cannot be completely avoided. Second, it only included a single-center cohort, and further external validation is required to demonstrate whether the present results are feasible for other patient cohorts. Thus, multicenter prospective studies are necessary to further clarify the relationship between different tumor growth patterns and prognosis in patients with 2–5 cm diameter gastric stromal tumors. Despite these limitations, the study provides valuable insights into clinical practice and highlights the need for clinicians to pay more attention to exogenous 2–5 cm diameter gastric mesenchymal tumors due to their higher risk of recurrence.
Conclusion
In conclusion, this retrospective study provides important insights into the relationship between tumor growth patterns and clinical outcomes in patients with 2–5 cm diameter gastric stromal tumors. Our results suggest that tumor growth patterns are independent predictors of progression-free survival, and that the exogenous type is associated with a significantly worse prognosis than the endogenous type. Therefore, we conclude that exogenous 2–5 cm diameter gastric stromal tumors have a high risk of recurrence and require the attention of clinicians.
Acknowledgements
The authors gratefully acknowledge all the investigators for their contributions to the trial.
Declarations
Ethics approval and consent to participate
The entire process of this study followed the ethical standards of Declaration of Helsinki and its later amendments. This study has been approved by the Ethics Committees of Nanjing Drum Tower Hospital, and informed consent was obtained from all subjects.
Anzeige
Consent for publication
None.
Competing interests
The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.
Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
